A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Trial details
- Registry ID
- NCT06908304
- Drugs studied
- 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Gemcitabine alone and 1 more
TrialRedline tracks 2 clinical trials sponsored by Maia Biotechnology: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304 | 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Gemcitabine alone and 1 more | Recruiting | 2027-07-31Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944 | 6-Thio-2'-Deoxyguanosine, Cemiplimab | Active not recruiting | 2027-09-30Estimated |
Names as written in the registry records.
NCT05208944 · Maia Biotechnology
Before: Recruiting. After: Active not recruiting.
NCT05208944 · Maia Biotechnology
Before: 30 Jun 2026. After: 30 Sep 2027.
NCT06908304 · Maia Biotechnology
Before: 29 Jul 2026. After: 31 Jul 2027.
Before: Not yet recruiting. After: Recruiting.